The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
eFFECTOR Therapeutics Inc COM 28202V108   1,519,900 4,309,329 SH   SOLE   4,309,329 0 0
NGM Biopharmaceuticals Inc COM 62921N105   73,997,879 18,136,735 SH   SOLE   18,136,735 0 0
ORIC Pharmaceuticals Inc. COM 68622P109   20,338,632 3,568,181 SH   SOLE   3,568,181 0 0
RAPT Therapeutics Inc COM 75382E109   49,189,395 2,680,621 SH   SOLE   2,680,621 0 0
Revolution Medicines Inc COM 76155X100   99,156,014 4,577,840 SH   SOLE   4,577,840 0 0
Surrozen, Inc. COM 86889P109   5,567,374 9,248,129 SH   SOLE   9,248,129 0 0
Tenaya Therapeutics, Inc. COM 87990A106   26,790,827 9,400,290 SH   SOLE   9,400,290 0 0